Opko

The deal is part of BioReference's ongoing effort to streamline its business to achieve profitability and follows the sale last year of clinical laboratory assets to Labcorp.

Of the 30 companies on the list, 22 firms saw their share prices decline month over month, while eight companies saw their stock prices rise.

The government alleges that BioReference submitted claims to federal healthcare programs for blood tests that were not ordered by a patient's provider.